Tag: XB002
Initial Dose-Escalation of First-in-Human Phase 1 JEWEL-101 Trial Evaluating XB002 in...
An ongoing, phase 1 dose-escalation study investigating XB002, Exelixis’ next-generation tissue factor-targeting antibody-drug conjugate (ADC) for the treatment of patients with advanced solid tumors, has shown promising results.
World ADC London 2022: What to Expect
With World ADC London staring later this week, excitement is building for the first in-person event in two years, with virtual attendance options available! With 70+ speakers...
Novasep and Exelixis Sign Manufacturing Services Agreement for XB002
Novasep and Exelixis have signed a manufacturing services agreement for the cGMP clinical production of XB002 (previously known as ICON-2), a next-generation tissue factor-targeting...
